Taiwan Bio Therapeutics , Ltd Overview
Get informed when a big investor buys or sells
+ Follow-51.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 6892.TWO is -51.73%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Taiwan Bio Therapeutics , Ltd's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 6892.TWO currently prints -51.73% for ROE, while the sector average sits near -100.59%. That is roughly 48.6% above the sector mean. Large gaps often invite a closer look at Taiwan Bio Therapeutics , Ltd's growth, margins, and balance sheet.
Return on Equity shows how effectively Taiwan Bio Therapeutics , Ltd converts resources into returns. At -51.73%, 6892.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6892.TWO's ROE (-51.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Taiwan Bio Therapeutics , Ltd's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
